Definite intensity-modulated radiotherapy with concurrent chemotherapy more than 4 cycles improved survival for patients with locally-advanced or inoperable esophageal squamous cell carcinoma

• Published in: The Kaohsiung journal of medical sciences Vol. 34; no. 5; pp. 281 - 289
• Main Authors: Hsieh, He-Yuan, Hsu, Chung-Ping, Yeh, Hui-Ling, Chuang, Cheng-Yen, Lin, Jai-Fu, Chang, Chen-Fa
• Format: Journal Article
• Language: English
• Published: China (Republic : 1949- ) Elsevier Taiwan 01.05.2018; Wiley
• Subjects: Adult; Aged; Aged, 80 and over; Antineoplastic Agents - therapeutic use; Carcinoma, Squamous Cell - diagnosis; Carcinoma, Squamous Cell - mortality; Carcinoma, Squamous Cell - pathology; Carcinoma, Squamous Cell - therapy; Chemoradiotherapy; Chemoradiotherapy - methods; Cisplatin - therapeutic use; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Administration Schedule; Esophageal neoplasms; Esophageal Neoplasms - diagnosis; Esophageal Neoplasms - mortality; Esophageal Neoplasms - pathology; Esophageal Neoplasms - therapy; Esophageal Squamous Cell Carcinoma; Female; Fluorouracil - therapeutic use; Follow-Up Studies; Gamma Rays - therapeutic use; Humans; Male; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Squamous cell carcinoma; Survival Analysis; Chemoradiotherapy; Squamous cell carcinoma; Esophageal neoplasms
• DOI: 10.1016/j.kjms.2017.12.005
• ISSN: 1607-551X; 2410-8650

We investigated which prognostic factor could improve survival for esophageal cancer patients who received definite concurrent chemoradiation (CCRT). Eighty patients with age ≥18, Karnofsky Performance Scale (KPS) ≥ 60, and clinical stage T1-4N0-3M0 esophageal squamous cell carcinoma were enrolled from July 2004 to December 2015. They underwent definite intensity-modulated radiotherapy (IMRT) with or without simultaneous integrated boost to the primary tumor, and reception of concurrent chemotherapy ≥ 1 cycle. The primary endpoints were overall survival (OS), locoregional progression-free survival (LRPFS) and distant metastasis-free survival (DMFS). The median follow-up duration for alive patients was 21.5 months. The rates of 2-, 3- and 5-year OS/LRPFS/DMFS were 23.8%/53.5%/49.3%, 19.1%/44.6%/49.3%, and 13.0%/44.6%/43.9%, respectively. Only the non-clinical complete response (non-cCR) after CCRT was an independent poor prognostic factor in OS (HR 3.101, 95% CI 1.535–6.265, p = 0.0016). Radiation dose >50.4 Gy and chemotherapy ≥4 cycles significantly predicted better LRPFS (p = 0.0361 and 0.0163, respectively). Poorly differentiated tumor and stage III disease have poor DMFS (p = 0.0336 and 0.0411, respectively), and chemotherapy ≥ 4 cycles was a better predictor (p = 0.0004). In subgroup analysis, patients who received radiation dose ≤50.4 Gy with concurrent chemotherapy ≥4 cycles had the best survival outcome with 1-, 2-, 3- and 5-year survival rates of 73.7%, 39.4%, 31.5% and 17.5%, respectively. In conclusion, definite radiotherapy with concurrent chemotherapy ≥4 cycles improved the survival for patients with inoperable or locally-advanced esophageal squamous cell carcinoma.